Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$13.92M
Gross Margin
-19.74%
TTM Avg
7.58%
3Y Avg
35.31%
5Y Avg
31.20%
Market Cap
$13.78M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.66M
Gross Margin
64.68%
TTM Avg
63.93%
3Y Avg
63.08%
5Y Avg
61.52%
Market Cap
$14.31M
Gross Margin
84.15%
TTM Avg
52.79%
3Y Avg
35.70%
5Y Avg
25.98%
Market Cap
$13.51M
Gross Margin
-486.44%
TTM Avg
-208.47%
3Y Avg
-109.22%
5Y Avg
-72.81%
Market Cap
$14.98M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2.45%
Market Cap
$12.78M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.17M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | -19.74% | 7.58% | 35.31% | 31.20% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.78M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | 64.68% | 63.93% | 63.08% | 61.52% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.31M | 84.15% | 52.79% | 35.70% | 25.98% |
| IN8bio, Inc. (INAB)vs › | $13.71M | 0.00% | 0.00% | 0.00% | 0.00% |
| Optimi Health Corp. (OPTH)vs › | $13.51M | -486.44% | -208.47% | -109.22% | -72.81% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.98M | 0.00% | 0.00% | 0.00% | -2.45% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | 0.00% | 0.00% | 0.00% | 0.00% |
| Passage Bio, Inc. (PASG)vs › | $13.24M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
